Efficacy and outcome of molecular targeted therapies in elderly patients with hepatocellular carcinoma: Relative dose intensity associated with overall survival.

Cancer Med · 2023 · PMC10757153 · PMID 38062925

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a slight trendno p-value reported

In contrast, the median OS for patients initiating first‐line treatment with lenvatinib was 743 and 526 days in the non‐elderly and elderly groups, respectively, with a slight trend toward shorter OS in the elderly patients.

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.